RxDoctor Payments DataLook up a doctor →

Edward Kim, MD

Urology · Knoxville, TNNPI 1316948029

Payments from drug & device makers

$52,368in general payments, 2019–2025

Across 441 payments — averaging $118.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$19K
  • Antares Pharma, Inc.$10K
  • Acerus Pharmaceuticals Corporation$9K
  • Axonics, Inc.$3K
  • Kowa Pharmaceuticals America, Inc.$2K
  • Coloplast$2K
  • plus $6K from 46 others

What the payments were for

  • Consulting fees$13,73726%
  • Speaking & faculty fees$19,97338%
  • Travel & lodging$5,87211%
  • Food & beverage$12,55624%
  • Education$2300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,368 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$431,269
Medicare patients
970
Services billed
6,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix115$300,906
XtandiEnzalutamide16$218,648
MyrbetriqMirabegron305$205,599
GemtesaVibegron265$202,686
ErleadaApalutamide12$167,548
ElmironPentosan Polysulfate Sodium38$26,598
PremarinEstrogens, Conjugated57$25,355
Mirabegron ErMirabegron22$12,625
Desmopressin Acetate177$10,389
Tamsulosin Hcl701$9,190
Potassium Citrate ErPotassium Citrate57$7,986
Testosterone51$7,968
Testosterone Cypionate252$7,226
Alfuzosin Hcl ErAlfuzosin Hcl330$5,965
Tolterodine Tartrate ErTolterodine Tartrate45$5,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$336$503,592380 claims
Astellas Pharma US IncXtandi, Myrbetriq$369$424,247321 claims
Johnson & JohnsonErleada$418$167,54812 claims
PfizerPremarin$97$25,35557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.

Other urology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →